2 years ago

OMass Therapeutics Secures £10 Million Extension to Series B for Drug Development

  • Oxford biotech spinout OMass Therapeutics has secured an additional £10 million in funding from British Patient Capital, extending its Series B round to £85.5 million

  • The company, which develops small molecule therapeutics for rare diseases and immunological conditions, will use the funds for clinical development

  • This latest investment brings OMass's total funding to £129 million.

      • ProblemHealthcare

      "Developing effective treatments for rare diseases and immunological conditions is challenging due to the complexity of the underlying biology and the difficulty in identifying druggable targets."

      Solution

      "OMass Therapeutics leverages a unique drug development platform combining novel biochemistry, native mass spectrometry, and custom chemistry to identify and target previously undruggable proteins, enabling the development of small molecule therapeutics for rare diseases and immunological conditions."

      Covered on